Meta-analysis of efficacy and safety of amlodipine in treatment of mild to moderate hypertension

Abstract

Abstract: AIM: To explore the efficacy and safety between amlodipine in treatment of mild to moderate hypertension.METHODS: The efficacy and safety of amlodipine or other drugs in treatment of mild to moderate hypertension were analyzed by Mata-analysis in homogeneity test and combined test in 25 investigations.RESULTS: Homogeneity test showed that the cited studies of efficacy and safety were homogeous with χ²_e=29.13, χ²_s=27.95, P>0.05, respectively;and in combined test, the combined OR_e=1.261, OR_s=1.013 and its 95% confidence interval were in 1.018-1.562 and 0.801-1.282, respectively.CONCLUSION: The efficacy of amlodipine is significantly superior to those of the medications used at present in treatment of mild to moderate hypertension, and its safety is reliable.

Key words: amlodipine, hypertension, efficacy, safety, Mata-analysis

CLC Number:

R969.4

ZHU Jin-xiu, LI Jian-chun, ZHENG Qing-shan. Meta-analysis of efficacy and safety of amlodipine in treatment of mild to moderate hypertension[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(2): 204-210.

References

1 Elkayam U, Amin J, Meha A.A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure[J].Circulation, 1990;82:1954-61
2 Goldstein RE, Boccuzzi SJ, Cruess D.Diltiazem increases lateonset congestive heart failure in postinfarction patients with early reduction injection fration[J].Circulation, 1991;83:52-60
3 俞朝阳, 彭放.氨氯地平在高血压治疗中的应用与临床药理[J].绍兴文理学院学报, 2002;22:104-7
4 王宪衍.氨氯地平与尼群地平治疗高血压的多中心平行对照研究[J].中国高血压杂志, 1994;2:104-7
5 张培云.氨氯地平与硝苯地平治疗高血压病的临床观察 [J].中国冶金工业医学杂志, 1995;12:335-8
6 王宪衍.氨氯地平152 例与尼群地平61 例治疗高血压病的比较[J].新药与临床, 1995;14:214-7
7 任伟.氨氯地平与尼群地平治疗老年高血压病的比较 [J].新药与临床, 1995;14:220-3
8 李愉荣.氨氯地平与卡妥普利治疗高血压的疗效比较 [J].山东医药, 1996;36:15
9 张建民.氨氯地平和比索洛尔治疗高血压病对比[J].滨州医学院学报, 1997;20:396
10 祝世法.氨氯地平与维拉帕米缓释片降压疗效的比较 [J].浙江医药, 1997;19:176-7
11 陈伟.氨氯地平与依那普利治疗高血压的对比研究[J]. 河南诊断与治疗杂志, 1997;11:146-8
12 陈泰丞.氨氯地平与尼群地平治疗高血压的比较[J].岭南心血管病杂志, 1998;4:193
13 李素芳.氨氯地平与尼群地平治疗高血压疗效比较[J]. 山西临床医药杂志, 1998;7:32-3
14 林绍彬.氨氯地平与尼群地平治疗老年高血压的疗效观察[J].心血管康复医学杂志, 1999;8:32-5
15 郑孟坚.氨氯地平与硝苯地平控释片对高血压病疗效比较[J].广东药学, 2000;10:41-3
16 王欢, 孙志军.福辛普利与氨氯地平治疗轻中度高血压疗效比较[J].辽宁药物与临床, 2000;3:67-8
17 殷屹岗.西拉普利和氨氯地平治疗原发性高血压的临床对照研究[J].铁道医学, 2000;2:373-5
18 刘嘉昌.氨氯地平与苯那普利对老年原发性高血压的疗效比较[J].上海铁道大学学报, 2000;2:28-32
19 毛月侠.氨氯地平与硝苯地平治疗原发性高血压的疗效比较[J].宁夏医学杂志, 2001;23:223-4
20 吕爱莲.氨氯地平和培哚普利对老年高血压病血压及血小板聚集功能的影响[J].中国现代医学杂志, 2001;11:47-9
21 曹志峰.氨氯地平、福辛普利、吲达帕胺降压效果的对比分析[J].中国医院药学杂志, 2001;21:297-8
22 杨昆.缬沙坦与氨氯地平治疗轻、中度原发性高血压的疗效比较[J].中国心血管杂志, 2001;6:103-5
23 薛兆利.氯沙坦与氨氯地平对比治疗高血压病72 例[J]. 中国新药杂志, 2001;10:455-6
24 薛兆利.氯沙坦与氨氯地平治疗高血压病的疗效观察 [J].中国医院药学杂志, 2001;21:298-9
25 闫亚非.非洛地平、氨氯地平及硝苯地平控释片降压效果对比观察[J].华西医学, 2001;16:52-3
26 付敏.氨氯地平、依那普利对高血压病肾功能影响的探讨[J].贵州医药, 2002;26:728-9
27 孙宁玲.北京降压0 号与氨氯地平治疗原发性高血压的临床对比试验[J].中国临床药理学杂志, 2002;18:171-3
28 朱正芳, 丁春玲.苯那普利治疗老年高血压疗效观察[J]. 实用临床医学, 2002;3:52-4
29 刘华玲.特拉唑嗪胶囊与氨氯地平片治疗原发性高血压的疗效比较[J].河南实用神经疾病杂志, 2003;6:53-4
30 蒋亚斌, 朱宁.降纤酶与其他药物治疗急性脑梗死对照研究的Meta 分析[J].中国临床药理学与治疗学, 2002;7: 496-9
31 富振英.Meta Analysis 研究资料的统计分析方法[J].药物流行病学杂志, 1994;3:220-14
32 刘关键, 王家良, 康德英.四格表数据Meta 分析的简明统计方法[J].华西医科大学学报, 2000;31:265-8
33 李俐.氨氯地平与培哚普利对高血压患者24 小时的降压疗效分析[J].中国厂矿医学, 2002;15:111-2
34 李晓宏.氨氯地平的药理及临床应用研究进展[J].徐州医学院学报, 2002;22:185-8

[1]	XU Yiqi, WU Qian, LIU Shu, LIU Fan, XING Chunyan, LI Qin, HE Junjun, HE Chunling, ZHAO Yongli, GAO Jialin. Clinical efficacy and anti-inflammation/anti-fibrosis effect of tripterygium glycosides in the treatment of diabetic nephropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1034-1042.
[2]	XIAO Yue, LI Tangfei, XUE Qianfu. Analysis of the efficacy and safety of Peg-IFN-α in the treatment of essential thrombocythemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1049-1055.
[3]	NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang. Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
[4]	JIA Boying, ZHOU Shuang, WAN Liyan, ZHOU Ying, CUI Yimin. Drug-induced dysphagia risk in elder people——A pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) database [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1109-1120.
[5]	LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HUANG Kai. Safety analysis on bioequivalence studies of orally inhaled drug products in healthy Chinese subjects#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1131-1138.
[6]	HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle. Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
[7]	SHEN Chang, AI Kelong, HU Changping. Research progress in the regulation of hypoxic pulmonary hypertension by hypoxia-inducible factor-1 signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 114-120.
[8]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[9]	CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
[10]	LIANG Meifang, CHEN Qingzhuang, YANG Peiqun, WANG Yong. Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: A real-world study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 785-792.
[11]	ZHANG Ningzhi, ZHAO Yuhong, TANG Minna, ZHANG Yongqiao, NING Sisi, CUI Zhaoqiang. Application of chronopharmacology in the hypertension treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 418-422.
[12]	CUI Sumei, CUI Zhaoqiang. Application of β-blockers for hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 423-427.
[13]	LI Yuanfang, CUI Zhaoqiang. Treatment of hypertension complicated with hyperuricemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 428-432.
[14]	XU Jianfei, LIN Li. Research progress in pharmacological and non-pharmacological treatments of hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 433-441.
[15]	KUAI Zheng, ZHANG Xiaoyi, ZOU Yunzeng. Angiotensin receptor neprilysin inhibitor in elderly with hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 442-445.